Pfizer Venture Investments (PVI), the venture capital arm of Pfizer Inc, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer.  PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.  In addition to Celladon, PVI's portfolio includes: Ablexis, Aquinox, Avid, Clovis Oncology, DVS, Evolution Benefits, Flexion, Genomic Health, Handylab, HD Biosciences, M2S, Merus, Neuronetics, NeuroTherapeutics Pharma, Nodality, NovoCure, and TetraLogic

Lundbeckfond Ventures is an evergreen life science venture fund established and wholly owned by the Lundbeck Foundation in the autumn of 2009. The structure as an open evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, Lundbeckfond Ventures invests in the order of € 30-50 million but will from time to time engage in larger investments through additional financial resources from the Lundbeck Foundation. The firm makes both venture and growth equity investments in both private and public companies and takes an active role in the companies invested in, typically taking board seats. Lundbeckfond Ventures invests mainly in Europe but also in the US and is a financially driven fund operating independently from the Lundbeck Foundation's controlling ownerships in H. Lundbeck, ALK-Abelló and Falck.

Novartis Venture Funds is one of the world's most active corporate investment funds with over $700MM under management.
We seek out investments in innovative life science concepts for patient benefit creating attractive returns for entrepreneurs and investors.  Our primary focus is on tnimal health. We enhance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to builhe development of novel therapeutics, and platforms for human health and we have recently extended our reach into ad the company and  follow with additional investment in pace with the company's progress. We continue our approach of larger focused investments and anticipate total investments up to USD 15 – 20 mio per company over its life, but it can be as little as 100'000 USD to get started. We lead or co-lead deals and remain open to participate in larger syndicates

Hambrecht & Quist Capital Management, LLC ("HQCM"), a registered investment adviser based in Boston, Massachusetts, is currently the investment adviser for two closed-end equity funds, H&Q Healthcare Investors and H&Q Life Sciences Investors. The Funds invest in growth equities, both public and private, in the healthcare and life sciences industries.